Gujarat Themis agrees to EUR 158 million Sanofi brand buy

Gujarat Themis has agreed to acquire 13 Sanofi tuberculosis and anti-infective brands for about EUR 158 million, covering a portfolio that generated about EUR 62 million in FY 2025. GTBL would receive brands, marketing authorisations, dossiers and inventory across more than 55 countries, without manufacturing assets or employee transfers.

What is GTBL acquiring from Sanofi?

GTBL is acquiring 13 established brands focused on tuberculosis and anti-infectives, with Levofloxacin, Rifampicin and Rifapentine identified as key molecules. The presentation classifies these molecules as World Health Organization essential and European Union critical medicines, linking the portfolio to areas that include GTBL's existing rifamycin products.

GTBL says the asset package includes brands, marketing authorisations, dossiers and inventory. Marketing authorisations are the regulatory approvals required to market medicines in particular jurisdictions, and the deal gives GTBL access to regulated markets across Europe, the Middle East and Africa, plus other markets within its 55-plus-country reach.

The portfolio is not described as an acquisition of Sanofi manufacturing operations. Instead, GTBL is acquiring commercial and regulatory assets attached to finished-dose brands, creating a route beyond its current intermediates and active pharmaceutical ingredients, or APIs, business.

How large is the GTBL Sanofi portfolio transaction?

The agreed deal value is about EUR 158 million, while the acquired portfolio recorded about EUR 62 million of FY 2025 actual revenue. GTBL presents the EUR 62 million as portfolio revenue, not as revenue already consolidated into its own financial statements.

About 70% of the portfolio's revenue comes from the retail channel, according to GTBL's deal snapshot. That channel exposure differs from an API-only supply arrangement because the transaction includes established brands positioned in market-facing, finished-dose distribution across more than 55 countries.

The presentation does not provide revenue by brand, country or therapeutic category. It also does not specify the contribution of Levofloxacin, Rifampicin or Rifapentine to the EUR 62 million of FY 2025 portfolio revenue.

How will GTBL fund and structure the Sanofi deal?

GTBL says it will fund the approximately EUR 158 million purchase through a mix of debt and equity. The presentation does not disclose the amount to be borrowed, the amount to be raised through equity, financing terms, potential share issuance or the transaction's expected completion date.

The transaction is structured as an asset acquisition of brands, marketing authorisations, dossiers and inventory. GTBL states that it will not acquire manufacturing assets, incur manufacturing capital expenditure, or take on employees through the transaction.

GTBL describes this structure as asset-light because it separates commercial-market access from ownership of factories and workforce. The company identifies API integration, cost optimisation and reactivation of dormant marketing authorisations as possible value levers, but it does not quantify savings, investment needs or a timetable for their delivery.

Why does the Sanofi portfolio fit GTBL's current products?

GTBL says the acquisition supports integration from intermediates to APIs and then finished dosages. Its current portfolio includes Rifamycin S, an intermediate for Rifampicin, and Rifamycin O, an intermediate for Rifaximin, while its anti-tuberculosis API range includes Rifampicin and Rifapentine.

The company lists intermediary capacity of up to 990 kilolitres. Because the acquired brands include Rifampicin and Rifapentine among their key molecules, GTBL sees scope for forward integration, although the presentation does not state what proportion of the acquired portfolio could eventually use GTBL-made API supply.

GTBL operates a plant in Vapi, Gujarat, with approximately 200 employees at the site. The presentation says GTBL was incorporated in 1981 and was India's first company to start commercial production of anti-tuberculosis drug Rifampicin, providing the stated fermentation and rifamycin background for the finished-dose portfolio move.

What financial context does GTBL report before the deal closes?

GTBL expects the acquisition to be earnings-per-share accretive and to have healthy gross margins. Management also cites possible additional upside from API integration, cost optimisation and dormant marketing-authorisation reactivation, but provides no earnings-per-share estimate or projected profit contribution.

On a standalone basis, GTBL's income from operations rose 16.7% to Rs 91.2 crore in H1 FY27 from Rs 78.2 crore in H1 FY26. Earnings before interest, tax, depreciation and amortisation, or EBITDA, increased 10.5% to Rs 38.5 crore from Rs 34.9 crore over the same comparison.

Despite the increase in standalone income and EBITDA, profit after tax fell 16.3% to Rs 19.5 crore from Rs 23.3 crore. EBITDA margin moved to 42.2% from 44.6%, and profit-after-tax margin declined to 21.4% from 29.8%; GTBL says commissioning of a new fermentation facility temporarily affected margins, with benefits expected from Q4 FY27.

Consolidated H1 FY27 income from operations was Rs 93.7 crore and EBITDA was Rs 19.9 crore, producing a 21.2% EBITDA margin. Consolidated profit after tax was a loss of Rs 2.8 crore, after GTBL cited Rs 15.57 crore of unrealised foreign-currency translation losses, Rs 1.2 crore of earthquake-related expenses at MicroBiopharm Japan Co., Ltd., and consolidation of only 13 days of that company's revenue following its September 18, 2026 acquisition.

Conclusion

The Sanofi agreement would take GTBL into branded finished-dose medicines while retaining its intermediates, API and fermentation base. The proposed EUR 158 million asset purchase brings 13 brands with about EUR 62 million in FY 2025 revenue, retail accounting for about 70% of sales, and market access across more than 55 countries without a stated transfer of factories or employees.

The next points to watch are the debt-and-equity funding split, the closing timetable and whether management quantifies expected earnings-per-share accretion. GTBL's disclosed value-creation plan depends on API integration, cost optimisation and dormant marketing-authorisation reactivation, while it also expects its new fermentation facility to begin providing benefits from Q4 FY27.